Animals (Dec 2024)

Comparative Analysis of Cross-Protective Immunity Among Three Geographically Distinct Isolates of <i>Eimeria kongi</i>

  • Sufang Fang,
  • Linghai Meng,
  • Yubo Shi,
  • Chengyu Hao,
  • Xiaolong Gu,
  • Fangchen Du,
  • Ping Cui,
  • Xinming Tang

DOI
https://doi.org/10.3390/ani14233524
Journal volume & issue
Vol. 14, no. 23
p. 3524

Abstract

Read online

Coccidiosis is one of the most significant diseases affecting the rabbit industry and is caused by Eimeria. In a previous study, we identified a new species of Eimeria kongi (E. kongi-ZJK) from the northern region of China (Zhangjiakou, Hebei Province) and studied its pathogenicity and immunogenicity. The aim of this study was to evaluate the pathogenicity, immunogenicity, and cross-immunogenicity from different geographical isolates of E. kongi for vaccine development. Two geographical isolates of E. kongi-QD from Qingdao, Shandong Province (eastern China), and E. kongi-CD from Chengdu, Sichuan Province (southwestern China), were isolated and identified. The pathogenicity, immunogenicity, and cross-immunogenicity among the three geographical isolates were evaluated. The pathogenicity results showed that after infecting rabbits with doses of 1 × 103 or fewer sporulated oocysts of E. kongi-QD and E. kongi-CD, the rabbits exhibited clinical symptoms but recovered quickly, indicating lower pathogenicity. Immunogenicity studies revealed that after immunizing rabbits with 1 × 103 sporulated oocysts of E. kongi-QD and E. kongi-CD for 14 days, followed by challenge with 1 × 104 homologous sporulated oocysts, the oocyst reduction rates in the immunized groups were 99.39% and 99.12%, respectively, compared with the non-immunized groups, demonstrating good immunogenicity. In cross-immunogenicity studies, rabbits were immunized with 1 × 103 sporulated oocysts of E. kongi-ZJK, E. kongi-QD, or E. kongi-CD and then challenged with 1 × 104 sporulated oocysts of heterologous isolate. The immunized groups showed no significant clinical symptoms, and the oocyst reduction rates ranged from 55.9% to 98.4%. E. kongi-CD exhibited cross-protection against E. kongi-ZJK and E. kongi-QD, making it an ideal candidate formulation for vaccine development.

Keywords